Dermapharm Holding SE (DMPHF) Comparison with companies in other sectors?

Dermapharm Holding SE has a share price of 53.84M. You can analyze Dermapharm Holding SE (DMPHF) competitors across different market sectors through stock heatmaps.

What are DMPHF's NET and operating margins?

Dermapharm Holding SE (DMPHF) operating margin is around 0.18, and net profit margin is approximately 0.09 as of the latest reports.

In what way does DMPHF's earnings per share (EPS) trend reflect its financial momentum?

Dermapharm Holding SE (DMPHF) EPS is 2.21 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Dermapharm Holding SE is 17.90, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Dermapharm Holding SE?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Dermapharm Holding SE like P/E which is 17.52, P/B which is 2.84, and PEG which is -2.29. Compare them with sector averages to evaluate if the stock is priced fairly.

Dermapharm Holding SE

DMPHF•PNK

Healthcare

Drug Manufacturers - Specialty & Generic

$39.56

$0.00(0.00%)

Fundamental Analysis of Dermapharm Holding SE (DMPHF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$2.21

P/E Ratio

17.90

ROE

0.17%

Net Margin

0.09%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.13B

Shares OutstandingTotal number of shares issued

$53.84M

Book Value/ShareNet worth per share

$11.92

Revenue/ShareAnnual revenue per share

$22.06

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$2.21

Net MarginNet income as percentage of revenue

8.71%

Operating MarginOperating income as percentage of revenue

17.76%

ROEReturn on shareholders' equity

17.42%

ROAReturn on total assets

4.90%

ROCEReturn on capital employed

11.69%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.44

Cash/ShareCash and equivalents per share

$2.19

FCF YieldFree cash flow as percentage of market cap

7.24%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.90

Dividend YieldAnnual dividend as percentage of stock price

2.67%

Financial Ratios Analysis data is not available for DMPHFFinancial Ratios Analysis details for DMPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for DMPHFSector Benchmarking details for DMPHF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Dermapharm Holding SE Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Dermapharm Holding SE. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Dermapharm Holding SE's unique business strengths and challenges.

Key Financial Metrics for Dermapharm Holding SE

For Dermapharm Holding SE, essential financial indicators include EPS 2.21, PE 17.90, and ROE 0.17. These key ratios reveal insights into Dermapharm Holding SE's profitability, valuation, and operational health. Understanding these metrics enables you to compare Dermapharm Holding SE with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Dermapharm Holding SE

Metrics like Net Margin 8.71% and ROA 4.90% shed light on how well Dermapharm Holding SE is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Dermapharm Holding SE can sustain its operations and continue growing in the future.

Valuation and Market Position of Dermapharm Holding SE

Using ratios such as P/B Ratio 2.84 and PEG Ratio -2.29, investors can assess whether Dermapharm Holding SE is appropriately valued based on its financials and growth potential. These figures, combined with Dermapharm Holding SE's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Dermapharm Holding SE

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow $2.44, provide a snapshot of Dermapharm Holding SE's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Dermapharm Holding SE, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Dermapharm Holding SE

Investing in Dermapharm Holding SE based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Dermapharm Holding SE focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;